US 12,187,756 B2
Stable vaccine against Clostridium difficile
Madhu Emmadi, Berlin (DE); Marilda P. Lisboa, Berlin (DE); Daniel Knopp, Berlin (DE); Bopanna Monnanda, Berlin (DE); Arne Von Bonin, Allschwil (CH); and Claney Lebev Pereira, Berlin (DE)
Assigned to IDORSIA PHARMACEUTICALS LTD, Allschwil (CH)
Appl. No. 17/296,194
Filed by IDORSIA PHARMACEUTICALS LTD, Allschwil (CH)
PCT Filed Nov. 22, 2019, PCT No. PCT/EP2019/082331
§ 371(c)(1), (2) Date May 21, 2021,
PCT Pub. No. WO2020/104697, PCT Pub. Date May 28, 2020.
Claims priority of application No. 18207920 (EP), filed on Nov. 22, 2018.
Prior Publication US 2023/0045939 A1, Feb. 16, 2023
Int. Cl. C07H 17/04 (2006.01); A61K 47/64 (2017.01)
CPC C07H 17/04 (2013.01) [A61K 47/646 (2017.08)] 33 Claims
 
1. A saccharide of general formula (I)

OG Complex Work Unit Chemistry
wherein
n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
T*- is —P(═O)(OH)2, —P(═O)(O−)(OH) or —PO32−;
Z is selected from

OG Complex Work Unit Chemistry
L is a linker;
E is —NH2, —N3, —CN, —O—NH2, —CH═CH2, —C≡CH, —Br, —Cl, —I, —CO2R′, —CONH—NH2, —SH, —OH or —SAc; and
R′ is —H, —Me, Et, 4-nitrophenyl, pentafluorophenyl, or N-succinimidyl;
or a diastereoisomer or a pharmaceutically acceptable salt thereof.